Cancer Research 'Under Review': What Each Status Means and When to Expect a Decision

Before the paper reaches external reviewers, a Cancer Research Senior Editor evaluates whether the cancer-research mechanism and broad cancer significance warrant Cancer Research's editorial slots. About 50 to 60 percent of submissions are desk-rejected at this stage within the AACR 3.8-day median desk decision.

A desk rejection most often means the Senior Editor concluded that the work would fit better at a sister AACR journal (Cancer Discovery for top-tier cancer discovery, Clinical Cancer Research for clinical-translation, Molecular Cancer Therapeutics for therapeutics, Cancer Prevention Research for prevention, Cancer Immunology Research for immunology, Cancer Epidemiology, Biomarkers & Prevention for epidemiology) or that the cancer-research mechanism bar is not met.

The Cancer Research editorial office confirms files are complete: manuscript with figures embedded, Supporting Information with cancer biology characterization data, AACR template formatting, reporting checklists where applicable (ARRIVE for animal work, MIQE for quantitative PCR, CONSORT for clinical-trial components), cover letter directed to the Senior Editor naming cancer-research mechanism contribution, conflict-of-interest declarations, ethics-statement documentation, IACUC approvals, and data-availability statement.

The Senior Editor reads the paper and evaluates cancer-research mechanism, broad cancer significance, and Cancer Research subspecialty routing. AACR's 3.8-day median desk decision is among the fastest in cancer biology publishing.

In parallel with the Senior Editor's primary read, ambiguous-fit papers are discussed across the AACR editorial team where peer Senior Editors weigh in on whether the paper would fit better at Cancer Research flagship or at sister AACR journals. This editor discussion runs alongside the desk-screen and adds 2 to 4 days to the timeline that is invisible to the author in the portal.

Cancer Research Senior Editors typically invite 2 to 3 reviewers, with reviewer recruitment typically taking 5 to 10 days. The recruitment includes at least one clinician-scientist for clinical-translation cancer-research papers, broadening the reviewer pool beyond pure basic-cancer-research expertise.

Once 2 to 3 reviewers agree to review, the typical Cancer Research peer-review cycle lasts 6 to 8 weeks per reviewer on average. 98 percent of first decisions with peer review had comments from 2 or more reviewers, indicating that Cancer Research successfully obtains the target number of reviews. Reviewer reports for Cancer Research tend to be thorough; 2000 to 4000 word reports are typical given the cancer-research mechanism complexity.

After reports return, the Senior Editor synthesizes them. Only 3.1 percent of Cancer Research decisions exceed 60 days, meaning the journal delivers fast decisions consistently. Total submission-to-acceptance commonly runs 4 to 8 months for successful papers, including revision rounds.

• Rejection within 1 to 3 days: Administrative issue or immediate scope mismatch.

• Rejection within 3 to 7 days: Senior Editor desk rejection per the AACR 3.8-day median.

• Still Under Review after 2 weeks: Strong signal. Paper passed the Cancer Research Senior Editor desk screen.

• Still Under Review after 8 weeks: You are past the slowest 3 percent (per AACR's 3.1 percent of decisions exceeding 60 days). A polite inquiry via the Editorial Manager portal is appropriate.

• Status changes to "Decision Pending": Reports are in; expect a decision within 1 week.

This is the most common anxiety we hear from Cancer Research authors during the active editorial window. The honest answer: no, 5 weeks at Under Review puts you right at Cancer Research's 35-day first-decision median. Reports may already be in editorial synthesis with the Senior Editor preparing the recommendation.

Most reviewer-driven delays come from clinician-scientist recruitment timing (Cancer Research typically includes at least one clinician-scientist among the 2 to 3 reviewers) rather than slow reviews. If the portal still says Under Review at the 8-week mark, you would be past the slowest 3 percent of Cancer Research decisions; a polite inquiry is appropriate.

What you should NOT do during the 5-to-8-week window is email the editorial office. Cancer Research Senior Editors are managing 60+ active papers per year around their own laboratories; an inquiry at 5 weeks adds friction without accelerating the timeline.

If your Cancer Research paper is rejected after review, the natural cascade depends on what the reviewers and Senior Editor cited:

Cancer Discovery is the natural AACR top-tier cancer discovery cascade. AACR supports manuscript-transfer with reviewer reports preserved via the AACR manuscript transfer pathway.

Clinical Cancer Research is the AACR cascade for clinical-translation papers. Clinical Cancer Research uses Editorial Manager at Editorial Manager submission portal; editorial contact ccrjournal@aacrjournals.org.

Molecular Cancer Therapeutics is the AACR cascade for therapeutics-focused work.

Cancer Prevention Research is the AACR cascade for cancer prevention.

Cancer Immunology Research is the AACR cascade for cancer immunology.

Cancer Epidemiology, Biomarkers & Prevention is the AACR cascade for cancer epidemiology and biomarkers.

Cancer Cell is the external Cell Press top-tier cancer cascade. Cancer Cell uses Editorial Manager at Editorial Manager submission portal; editorial contact cancercell@cell.com.

Nature Cancer is the external Springer Nature top-tier cancer cascade.

AACR asks reviewers at Cancer Research to evaluate four things specifically. The table below maps each to actionable preparation.

In our pre-submission work with Cancer Research-targeted manuscripts, three named patterns generate the most consistent reviewer concerns and the most common reasons papers miss the editorial bar or fail the desk screen.

Narrow cancer-subtype framing flagged at Senior Editor desk screen. When the Cancer Research introduction frames the work too narrowly within one cancer subtype without a broader cancer-research mechanism, Senior Editor desk rejection within the fast AACR triage window is common. The strongest manuscripts make the mechanism visible in the title, abstract, model choice, and first figure, then show why the finding matters beyond the immediate tumor type.

If the abstract only says that a marker is associated with outcome in one cohort, the Senior Editor can often decide before external reviewer recruitment that the paper fits a more specialist AACR or disease-specific venue.

Check whether your Cancer Research mechanism is broad enough →

Clinician-scientist methodology gaps surface as reviewer concerns. When Cancer Research clinical-translation components are present but clinician-scientist methodology is thin, the clinician-scientist reviewer consistently flags the sample-size rationale, randomization, blinding, endpoint definition, and cohort-selection language. The strongest revisions complete CONSORT coverage for any clinical-trial component and align the methods, supplementary tables, and figure legends so the clinical claim does not outrun the evidence package.

Check your Cancer Research clinical-methods package →

AACR family cascade offers from Senior Editor. When the Cancer Research Senior Editor concludes the work is rigorous but the cancer-research mechanism bar is not met, transfer offers to Cancer Discovery, Clinical Cancer Research, Molecular Cancer Therapeutics, or other AACR journals are common. AACR editors take these transfers seriously and the manuscript transfer pathway can preserve reviewer reports.

The decision letter matters: a cascade after a broad-significance concern often means the figure package is sound but the story should be re-aimed, while a cascade after methods concerns usually requires deeper changes before transfer.

Check whether Cancer Research or an AACR sister journal is the better fit →

We have reviewed 50+ manuscripts targeting Cancer Research, Clinical Cancer Research, Cancer Cell, Nature Cancer, and AACR sister journals. This guide tells you what Cancer Research editors look for in the status window, while the review tells you whether your paper passes the same mechanism, figure-order, clinical-methods, and broad-significance checks before the Senior Editor or external reviewers see it. Full Manusights reviews include a 60-day money-back guarantee, and we do not train models on your manuscript.

We have found that the strongest Cancer Research revisions preserve the same mechanism claim across the title, abstract, first figure, and response letter instead of trying to repair fit only in the cover letter.

In our pre-submission review work across cancer-mechanism and translational oncology targets, Cancer Research-bound drafts most often failed when the central mechanism claim shifted between the abstract, figure sequence, and discussion. We see that inconsistency as a recurring failure pattern because AACR editors can catch the mismatch before external reviewers are invited. Source limitation: official guidance explains AACR editorial workflow and reviewer expectations, but it cannot tell you whether your specific figure order proves the mechanism at Cancer Research depth.

Use this guide when you need to separate normal AACR review silence from a true follow-up moment before you submit, withdraw, or prepare a transfer plan.

This page was created from AACR's public editorial process documentation at Aacrjournals editorial team page, AACR author services center documentation (3.8-day median desk decision, 35-day median first decision with peer review, only 3.1 percent of decisions exceeding 60 days, 98 percent of first decisions with peer review having 2 or more reviewer comments, AACR manuscript transfer pathway for inter-AACR-journal cascades, typical inclusion of at least one clinician-scientist among 2 to 3 reviewers), and Manusights pre-submission review experience with Cancer Research-targeted manuscripts.

For the AACR cancer landscape beyond Cancer Research, see Cancer Discovery (top-tier cancer discovery), Clinical Cancer Research (clinical-translation), Molecular Cancer Therapeutics (therapeutics), Cancer Prevention Research (prevention), Cancer Immunology Research (immunology), Cancer Epidemiology, Biomarkers & Prevention (epidemiology), and external cancer alternatives (Cancer Cell, Nature Cancer).

The choice across these titles depends on whether the central contribution is top cancer-research mechanism (Cancer Research), top cancer discovery (Cancer Discovery), clinical-translation (Clinical Cancer Research), therapeutics (Molecular Cancer Therapeutics), prevention (Cancer Prevention Research), immunology (Cancer Immunology Research), epidemiology (Cancer Epidemiology, Biomarkers & Prevention), Cell Press top-tier cancer (Cancer Cell), or Nature Portfolio top-tier cancer (Nature Cancer).

Reviewers at Cancer Research typically draw from 2 to 3 cancer biology subspecialty experts (typically including at least one clinician-scientist) under the AACR single-blind model. Editors screen and triage manuscripts before any reviewer sees them, and preparing a response template that addresses both basic-cancer-research and clinician-scientist perspectives accelerates revision rounds substantially.

For a pre-upload check of your manuscript against the Cancer Research cancer-research-mechanism bar before submission, our Cancer Research pre-submission diagnostic flags the framing and methodology weaknesses most likely to surface in reviewer reports.